<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1274" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1274/" /><meta name="ncbi_pagename" content="Mucopolysaccharidosis Type II - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Mucopolysaccharidosis Type II - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Mucopolysaccharidosis Type II" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/10/04" /><meta name="citation_author" content="Maurizio Scarpa" /><meta name="citation_pmid" content="20301451" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1274/" /><meta name="citation_keywords" content="Hunter Syndrome" /><meta name="citation_keywords" content="Iduronate-2-Sulfatase Deficiency" /><meta name="citation_keywords" content="MPS II" /><meta name="citation_keywords" content="Hunter Syndrome" /><meta name="citation_keywords" content="MPS II" /><meta name="citation_keywords" content="Iduronate-2-Sulfatase Deficiency" /><meta name="citation_keywords" content="Iduronate 2-sulfatase" /><meta name="citation_keywords" content="IDS" /><meta name="citation_keywords" content="Mucopolysaccharidosis Type II" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Mucopolysaccharidosis Type II" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Maurizio Scarpa" /><meta name="DC.Date" content="2018/10/04" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1274/" /><meta name="description" content="Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of affected individuals are male; on rare occasion heterozygous females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome." /><meta name="og:title" content="Mucopolysaccharidosis Type II" /><meta name="og:type" content="book" /><meta name="og:description" content="Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of affected individuals are male; on rare occasion heterozygous females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1274/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hunter/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1274/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88D496E03FBB110000000006390204.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1274_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1274_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mps1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mps3/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1274_"><span class="title" itemprop="name">Mucopolysaccharidosis Type II</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Hunter Syndrome, Iduronate-2-Sulfatase Deficiency, MPS II</div><p class="contrib-group"><span itemprop="author">Maurizio Scarpa</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1274_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1274_ai__"><div class="contrib half_rhythm"><span itemprop="author">Maurizio Scarpa</span>, MD, PhD<div class="affiliation small">Center For Rare Diseases<br />Department of Pediatric and Adolescent Medicine<br />Horst Schmidt Klinik<br />Wiesbaden, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.nekinilk-soileh@apracs.oiziruam" class="oemail">ed.nekinilk-soileh@apracs.oiziruam</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 6, 2007</span>; Last Update: <span itemprop="dateModified">October 4, 2018</span>.</p><p><em>Estimated reading time: 30 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hunter.Summary" itemprop="description"><h2 id="_hunter_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are male; on rare occasion <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of MPS II is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of deficient iduronate 2-sulfatase (I2S) enzyme activity in white cells, fibroblasts, or plasma in the presence of normal activity of at least one other sulfatase. Detection of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>IDS</i> confirms the diagnosis in a male proband with an unusual <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> or a phenotype that does not match the results of GAG testing. The diagnosis of MPS II is usually established in a female proband with suggestive clinical features by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>IDS</i> pathogenic variant on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Interventions commonly include: developmental, occupational, and physical therapy; shunting for hydrocephalus; tonsillectomy and adenoidectomy; positive pressure ventilation (CPAP or tracheostomy); carpal tunnel release; cardiac valve replacement; inguinal hernia repair; hip replacement.</p><p><i>Prevention of primary manifestations</i>: Weekly enzyme replacement therapy (ERT) with infusions of idursulfase (Elaprase<sup>&#x000ae;</sup>), a recombinant form of human iduronate 2-sulfatase, is approved to treat somatic manifestations and prolong survival. Pretreatment with anti-inflammatory drugs or antihistamines may be needed for mild or moderate infusion reactions. Hematopoietic stem cell transplantation (HSCT) (using umbilical cord blood or bone marrow) could provide sufficient enzyme activity to slow or stop the progression of the disease; however, no controlled clinical studies have been conducted in MPS II.</p><p><i>Prevention of secondary complications</i>: Anesthesia is best administered in centers familiar with the potential complications in persons with MPS II.</p><p><i>Surveillance</i>: Depends on organ system and disease severity and usually includes annual: cardiology evaluation and echocardiogram; pulmonary evaluation including pulmonary function testing; audiogram; ophthalmology examination; developmental assessment; neurologic examination. Additional studies may include: sleep study for obstructive apnea; nerve conduction velocity to assess for carpal tunnel syndrome; head/neck MRI to document ventricular size and cervicomedullary narrowing; opening pressure on lumbar puncture; and orthopedic evaluation to monitor hip disease.</p><p><i>Evaluation of relatives at risk</i>: While clinical experience suggests that early diagnosis of at-risk males allows initiation of ERT before the onset of irreversible changes and often before significant disease progression, it is unclear at present whether the potential benefits of early initiation of ERT justify early diagnosis by either <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> or testing of at-risk male relatives.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>MPS II is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. The risk to sibs depends on the genetic status of the mother. If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be carriers. Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been observed. Affected males pass the pathogenic variant to all of their daughters and none of their sons. Carrier testing for at-risk female relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant in the family is known.</p></div></div><div id="hunter.Diagnosis"><h2 id="_hunter_Diagnosis_">Diagnosis</h2><p>The diagnosis of mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) cannot be made on clinical findings alone. The specific combination of signs and symptoms and their physical manifestation vary widely, depending on disease severity, and the evolution of individual manifestations over time is often a better indicator of a diagnosis of MPS II.</p><p>Recommendations for the diagnosis and management of MPS II have been developed by the Hunter Syndrome European Expert Council (HSEEC) using an evidence-based approach [<a class="bk_pop" href="#hunter.REF.scarpa.2011.72">Scarpa et al 2011</a>].</p><div id="hunter.Suggestive_Findings"><h3>Suggestive Findings</h3><p>MPS II <b>should be suspected</b> in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following clinical, radiographic, and laboratory findings.</p><p><b>Clinical features common at age 18 months to four years</b></p><ul><li class="half_rhythm"><div>Short stature</div></li><li class="half_rhythm"><div>Hepatosplenomegaly</div></li><li class="half_rhythm"><div>Joint contractures</div></li><li class="half_rhythm"><div>Coarse facies</div></li><li class="half_rhythm"><div>Frequent ear/sinus infections</div></li><li class="half_rhythm"><div>Umbilical hernia</div></li></ul><p><b>Radiographic findings.</b> Skeletal survey reveals dysostosis multiplex (i.e., generalized thickening of long bones, particularly the ribs; irregular epiphyseal ossification centers in many areas; notching of the vertebral bodies).</p><p>Note: These findings may not be present in early life and are not specific to MPS II.</p><p><b>Laboratory findings.</b> Urine glycosaminoglycan (GAG) analysis shows large concentrations of the GAGs dermatan sulfate and heparan sulfate.</p><p>Note: These findings are not specific to MPS II; the profile is similar to that seen in <a href="/books/n/gene/mps1/">MPS I</a>.</p></div><div id="hunter.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of MPS II <b>is established</b> in a male proband by identification of absent or reduced iduronate 2-sulfatase (I2S) enzyme activity in white cells, fibroblasts, or plasma. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males have no detectable activity using the artificial substrate. Detailed analytic protocols for measurement of I2S enzyme activity have been published [<a class="bk_pop" href="#hunter.REF.johnson.2013.17">Johnson et al 2013</a>]. Note: Documentation of normal enzymatic activity of at least one other sulfatase is critical, as low levels of I2S enzyme activity are present in multiple sulfatase deficiency, which can share some clinical features with MPS II.</p><p>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1274/table/hunter.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="fighunterTmoleculargenetictestingused" rid-ob="figobhunterTmoleculargenetictestingused">Table 1</a>) confirms the diagnosis of MPS II in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and may be useful in persons with an unusual <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> or a phenotype that does not match the results of GAG analysis.</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Although the disease is almost exclusively reported in males, rare <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> cases in females do occur. The diagnosis of MPS II <b>is usually established</b> in a female proband <b>presenting with</b>
<a href="#hunter.Suggestive_Findings">suggestive clinical features</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1274/table/hunter.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="fighunterTmoleculargenetictestingused" rid-ob="figobhunterTmoleculargenetictestingused">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of MPS II is broad, individuals with the distinctive findings described in <a href="#hunter.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#hunter.Option_1">Option 1</a>), whereas those in whom the diagnosis of MPS II has not been considered are more likely to be diagnosed using genomic testing (see <a href="#hunter.Option_2">Option 2</a>).</p><div id="hunter.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of MPS II, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>IDS</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>IDS</i> and other genes of interest (see <a href="#hunter.Differential_Diagnosis">Differential Diagnosis</a>) may be considered to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1274/table/hunter.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="fighunterTmoleculargenetictestingused" rid-ob="figobhunterTmoleculargenetictestingused">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="hunter.Option_2"><h4>Option 2</h4><p>When the diagnosis of MPS II is not considered because an individual has atypical phenotypic features, <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p><b>Exome array</b> (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="hunter.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in MPS II (Hunter Syndrome)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1274/table/hunter.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hunter.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>IDS</i></td><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">82%&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td></tr><tr><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Complex rearrangements&#x000a0;<sup>8</sup></td><td headers="hd_h_hunter.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hunter.TF.1.1"><p class="no_margin">See <a href="/books/NBK1274/#hunter.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hunter.TF.1.2"><p class="no_margin">See <a href="#hunter.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hunter.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hunter.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="hunter.TF.1.5"><p class="no_margin">Single-nucleotide changes and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants account for 65% of all pathogenic variants; small (i.e., intra-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>) deletions and insertions account for 17% of all pathogenic variants [<a class="bk_pop" href="#hunter.REF.froissart.2007.71">Froissart et al 2007</a>].</p></div></dd><dt>6. </dt><dd><div id="hunter.TF.1.6"><p class="no_margin">Sequence analysis may not detect complex rearrangements in males or females that result from a common pathogenic inversion between <i>IDS</i> and <i>IDSP1</i>.</p></div></dd><dt>7. </dt><dd><div id="hunter.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="hunter.TF.1.8"><p class="no_margin">Complex rearrangements result from <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> with the <i>IDSP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a> or from other types of processes. Testing may require multiple molecular methods (e.g., sequencing, SNP analysis, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a>) to confirm and map rearrangement breakpoints [<a class="bk_pop" href="#hunter.REF.lualdi.2005.491">Lualdi et al 2005</a>, <a class="bk_pop" href="#hunter.REF.froissart.2007.71">Froissart et al 2007</a>, <a class="bk_pop" href="#hunter.REF.oshima.2011.516">Oshima et al 2011</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="hunter.Clinical_Characteristics"><h2 id="_hunter_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hunter.Clinical_Description"><h3>Clinical Description</h3><p>Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) has multisystem involvement with significant variability in both age of onset and rate of progression.</p><p>CNS involvement, the most significant feature in the group of children often labeled with "early progressive" disease, manifests primarily by progressive cognitive deterioration. Such cognitive decline, combined with the progressive airway and cardiac disease, usually results in death in the first or second decade of life.</p><p>In individuals with the slowly progressive form of the disease, the CNS is minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, if at all, yet the effect of glycosaminoglycan (GAG) accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in this group.</p><p>The early progressive CNS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be more than twice as prevalent as the slowly progressive form of the disease; however, accurate prevalence rates are not available. Some form of neurologic involvement is seen in 84% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. Cardiovascular involvement was reported in 82% of affected individuals [<a class="bk_pop" href="#hunter.REF.wraith.2008.508">Wraith et al 2008</a>].</p><p>In individuals with MPS II, GAG accumulation occurs in virtually all organs; however, specific body systems are more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than others.</p><p>Following are the clinical presentations of the organ systems that are earliest and most progressively <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in individuals with MPS II.</p><div id="hunter.General"><h4>General</h4><p>The appearance of newborns with MPS II is normal. Coarsening of facial features &#x02013; the result of macroglossia, prominent supraorbital ridges, a broad nose, a broad nasal bridge, and deposition of GAG in the soft tissues of the face resulting in large rounded cheeks and thick lips &#x02013; generally manifests between ages 18 months and four years in the early progressive form and about two years later for those with the slowly progressive form. Some develop ivory-colored skin lesions on the upper back and sides of the upper arms, pathognomonic of MPS II [<a class="bk_pop" href="#hunter.REF.tylkiszyma_ska.2014.107">Tylki-Szyma&#x00144;ska 2014</a>].</p></div><div id="hunter.Growth"><h4>Growth</h4><p>For most boys with MPS II growth is above average in the first five years of life, after which growth lags and short stature is the norm. Macrocephaly is universal.</p><p>Although no statistical difference is observed between height in the slowly progressive and early progressive phenotypes, the growth pattern can help in monitoring disease progression and assessing therapeutic efficacy [<a class="bk_pop" href="#hunter.REF.patel.2014.5">Patel et al 2014</a>].</p></div><div id="hunter.Eye"><h4>Eye</h4><p>In contrast to <a href="/books/n/gene/mps1/">MPS I</a>, corneal clouding occurs occasionally and is not a typical feature of MPS II. However, discrete corneal lesions that do not affect vision may be discovered by slit lamp examination.</p><p>Optic nerve head swelling (papilledema) in the absence of increased intracranial pressure is present in approximately 20% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and subsequent optic atrophy in approximately 11% [<a class="bk_pop" href="#hunter.REF.collins.1990.1445">Collins et al 1990</a>, <a class="bk_pop" href="#hunter.REF.ashworth.2006.1">Ashworth et al 2006</a>], mainly as a result of scleral thickening due to GAG deposition.</p><p>Retinopathy has been reported most commonly in individuals with early progressive MPS II, although it can also be present in individuals with the slowly progressive form. Progressive reduction in ERG amplitude suggests deterioration in retinal function [<a class="bk_pop" href="#hunter.REF.leung.1971.32">Leung et al 1971</a>]. Retinal degeneration leads to poor peripheral vision and night blindness, which occur frequently in individuals with MPS II, while central visual impairment due to retinal degeneration is rare [<a class="bk_pop" href="#hunter.REF.suppiej.2013.1203">Suppiej et al 2013</a>]. Such retinal dysfunction can be revealed by electroretinography (ERG). Visual field loss can also occur: initially, rod-mediated responses are more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by early progression than cone-mediated responses [<a class="bk_pop" href="#hunter.REF.caruso.1986.1612">Caruso et al 1986</a>]. However, signs and symptoms do not necessarily correlate with ERG change, as often only minimal changes are observed in the retinal pigment epithelium despite significant ERG changes [<a class="bk_pop" href="#hunter.REF.ashworth.2006.1">Ashworth et al 2006</a>].</p><p>Other ocular findings include bilateral uveal effusions, peripheral pigment epithelial changes, and radial parafoveal folds [<a class="bk_pop" href="#hunter.REF.ashworth.2006.1">Ashworth et al 2006</a>].</p></div><div id="hunter.Ear_Nose_Throat"><h4>Ear, Nose, Throat</h4><p>Common oral findings in boys with MPS II include macroglossia, hypertrophic adenoids and tonsils, and ankylosis of the temporomandibular joint, which limits opening of the mouth. These changes may be responsible for progressive swallowing impairment. GAG deposition in the larynx typically results in a characteristic hoarse voice.</p><p>Teeth are often irregularly shaped and gingival tissue is overgrown. Dentigenous cysts can occur, often causing pain and discomfort. They can be difficult to diagnose particularly in males with CNS involvement.</p><p>Conductive and sensorineural hearing loss, complicated by recurrent ear infections, occurs in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Otosclerosis can contribute to the conductive hearing loss. Neurosensory hearing loss can be attributed to compression of the cochlear nerve resulting from arachnoid hyperplasia, reduction in the number of spiral ganglion cells, and degeneration of hair cells.</p></div><div id="hunter.JointsSkeletal"><h4>Joints/Skeletal</h4><p>Joint contractures, particularly of the phalangeal joints, are universal. The contractures cause significant loss of joint mobility and are one of the earliest noteworthy diagnostic clues.</p><p>The skeletal abnormalities in MPS II are comparable regardless of the severity of the cognitive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> but are not specific to MPS II. Termed "dysostosis multiplex," these radiographic findings are found in all MPS disorders and manifest as a generalized thickening of most long bones, particularly the ribs, with irregular epiphyseal ossification centers in many areas. Notching of the vertebral bodies is common.</p><p>Hip dysplasia is the most common long-term orthopedic problem and can become a significant disability with early-onset arthritis if not treated.</p></div><div id="hunter.Respiratory"><h4>Respiratory</h4><p>Frequent upper-respiratory infections are one of the earliest findings in MPS II. The airway progressively narrows as GAGs accumulate in the tongue, soft tissue of the oropharynx, and the trachea, eventually leading to airway obstruction. Complicating this obstruction are thickening of respiratory secretions, stiffness of the chest wall, and hepatosplenomegaly, which can reduce thoracic volume. The progression of airway obstruction is relentless and usually results in sleep apnea and the need for positive pressure assistance and eventually tracheostomy.</p></div><div id="hunter.Cardiovascular"><h4>Cardiovascular</h4><p>The heart is abnormal in the majority of boys with MPS II and is a major cause of morbidity and mortality; 82% of individuals have cardiovascular signs/symptoms, 62% have a murmur that can be related to valvular disease, including (in order of frequency) the mitral, aortic, tricuspid, and pulmonary valves. Cardiomyopathy, hypertension, rhythm disorder, and peripheral vascular disease are seen occasionally (&#x0003c;10%) [<a class="bk_pop" href="#hunter.REF.wraith.2008.508">Wraith et al 2008</a>].</p></div><div id="hunter.Gastrointestinal"><h4>Gastrointestinal</h4><p>Hepatomegaly and/or splenomegaly occur in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Umbilical/inguinal hernia is also a frequent finding. In persons with early progressive MPS II, chronic diarrhea is a common complaint.</p></div><div id="hunter.Nervous_System"><h4>Nervous System</h4><p>Infants with MPS II appear normal at birth; early developmental milestones may also be within the normal range. Delay in global developmental milestones is typically the first indication of brain involvement in children with the CNS form of MPS II. Presence of sleep disturbance, increased activity, behavior difficulties, seizure-like behavior, perseverative chewing behavior, and inability to achieve bowel and bladder training may be strongly correlated with subsequent cognitive dysfunction [<a class="bk_pop" href="#hunter.REF.holt.2011.320">Holt et al 2011</a>].</p><p>As is the case for the other organ systems, progression of the CNS manifestations is inexorable, usually resulting in developmental regression between ages six and eight years.</p><p>The most common neurologic signs are behavioral and cognitive problems, which <a class="bk_pop" href="#hunter.REF.wraith.2008.508">Wraith et al [2008]</a> found in 36% and 37% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, respectively. Behavioral problems occur in both the early progressive and slowly progressive forms of the disease [<a class="bk_pop" href="#hunter.REF.young.1981.201">Young &#x00026; Harper 1981</a>, <a class="bk_pop" href="#hunter.REF.wraith.2008.508">Wraith et al 2008</a>] but are more common in the early progressive form.</p><p>Chronic communicating hydrocephalus may complicate the clinical picture, especially on the background of deteriorating cognitive ability. Seizures may also occur.</p><p>The decline of cognitive function, combined with progression of early progressive pulmonary and cardiac disease, generally heralds the terminal phase of the disease, with death in the first or second decade of life.</p><p>Males who do not have the progressive CNS form of the disease have normal or near-normal intelligence. However, while deteriorating cognitive abilities and seizures are not common in males with the slowly progressive form of MPS II, chronic communicating hydrocephalus may still occur.</p><p>Carpal tunnel syndrome (CTS) is often an overlooked complication of MPS II. Unlike adults with CTS, most children with MPS II do not complain of the typical symptoms. Nonetheless, nerve conduction studies are abnormal. Hand function improves after surgical correction.</p><p>Another nervous system complication that must be monitored is narrowing of the spinal canal (spinal stenosis), particularly in the cervical region, with spinal cord compression.</p></div><div id="hunter.Endocrine"><h4>Endocrine</h4><p>Infants with MPS II appear normal at birth; in the first years of life the height of most children with MPS II is above the 50th percentile and in some it is over the 97th percentile. However, growth velocity decreases with age. By age eight years, height is below the third percentile, and nearly all children exhibit growth retardation before puberty [<a class="bk_pop" href="#hunter.REF.schulzefrenking.2011.203">Schulze-Frenking et al 2011</a>]. The cause of short stature is unknown; it may be related to osseous growth-plate disturbances.</p></div></div><div id="hunter.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Limited information is available regarding <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>:</p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1274/table/hunter.T.ids_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="fighunterTidspathogenicvariantsdiscuss" rid-ob="figobhunterTidspathogenicvariantsdiscuss">c.1122C&#x0003e;T</a> (which creates a new donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> at <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 with the loss of 20 amino acids) is primarily associated with the slowly progressive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#hunter.REF.muenzer.2009.e1228">Muenzer et al 2009</a>].</div></li><li class="half_rhythm"><div>Males with complete absence of functional enzyme as a result of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or complex gene rearrangements (~17% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) invariably manifest the early progressive CNS presentation of the disease [<a class="bk_pop" href="#hunter.REF.wraith.2008.508">Wraith et al 2008</a>].</div></li><li class="half_rhythm"><div>Recent data from a cohort study of Dutch individuals with MPS II suggest that very low or cell-type-specific IDS residual activity is sufficient to prevent the neuronal <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of MPS II. While the molecular effects of <i>IDS</i> pathogenic variants do not discriminate between MPS II phenotypes, the IDS <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is indicated as a strong predictor [<a class="bk_pop" href="#hunter.REF.vollebregt.2017.1063">Vollebregt et al 2017</a>].</div></li></ul></div><div id="hunter.Penetrance"><h3>Penetrance</h3><p>Penetrance of MPS II in males is complete; however, it is anticipated that if <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> becomes available for MPS II, much milder presentations would be documented.</p></div><div id="hunter.Nomenclature"><h3>Nomenclature</h3><p>The modifier terms "mild/attenuated" and "severe" were often used in the past to describe the phenotypic variability of the condition, but it is clear (as for all MPS disorders) that the range of severity is wide. It is now considered inappropriate to use these terms since the disease significantly alters the quality of life. Thus, the terms "slowly progressive" (to describe the former "attenuated" form of the disease) and "early progressive" (to describe the form of the disease previously designated "severe") are currently being considered to better reflect the continuum of disease severity.</p></div><div id="hunter.Prevalence"><h3>Prevalence</h3><p>Several surveys suggest an incidence between 1:100,000 and 1:170,000 male births [<a class="bk_pop" href="#hunter.REF.nelson.2003.310">Nelson et al 2003</a>, <a class="bk_pop" href="#hunter.REF.baehner.2005.1011">Baehner et al 2005</a>].</p></div></div><div id="hunter.Genetically_Related_Allelic_Disor"><h2 id="_hunter_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>Deletions extending beyond the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> result in symptoms atypical of MPS II. These deletions cause an earlier progressive central nervous system <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and may be associated with other atypical features such as ptosis and seizures [<a class="bk_pop" href="#hunter.REF.probst.2007.1358">Probst et al 2007</a>].</p></div><div id="hunter.Differential_Diagnosis"><h2 id="_hunter_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis for mucopolysaccharidosis type II (MPS II, or Hunter syndrome) essentially includes all of the other MPS disorders, given the significant overlap of clinical presentation and radiologic findings (see <a href="/books/n/gene/mps1/">MPS I</a>).</p><p>Multiple sulfatase deficiency and mucolipidosis types II and III may also present with findings similar to MPS II. See: <a href="/books/n/gene/ml2/">Mucolipidosis II</a>, <a href="/books/n/gene/ml3a/">Mucolipidosis III Alpha/Beta</a>, and <a href="/books/n/gene/ml3c/">Mucolipidosis III Gamma</a>.</p><p>See <a href="http://omim.org/phenotypicSeries/PS607014" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mucopolysaccaridoses: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="hunter.Management"><h2 id="_hunter_Management_">Management</h2><div id="hunter.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with mucopolysaccharidosis type II (MPS II), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Echocardiogram</div></li><li class="half_rhythm"><div>Pulmonary function testing preferably in individuals age six years and older. Pulmonary function testing (e.g., spirometry) can be quite challenging in younger individuals and may be impossible for individuals with significant CNS involvement since it requires their full cooperation and is effort dependent [<a class="bk_pop" href="#hunter.REF.kamin.2008.57">Kamin 2008</a>].</div></li><li class="half_rhythm"><div>Sleep study if sleep apnea is a potential concern or in case of sleep disturbances not related to upper airway obstruction or impairment of ventilatory control (e.g., difficulty initiating or maintaining sleep, awakening several times per night, decreased REM sleep, atypical sleep stage distribution, and restless legs), which might start to manifest at a median age of four to five years [<a class="bk_pop" href="#hunter.REF.rapoport.2017.49">Rapoport &#x00026; Mitchell 2017</a>]</div></li><li class="half_rhythm"><div>Audiologic evaluation</div></li><li class="half_rhythm"><div>Nerve conduction velocity (NCV) and nerve ultrasound examination to assess for carpal tunnel syndrome</div></li><li class="half_rhythm"><div>Head-cervical MRI and/or opening pressure on lumbar puncture to assess for hydrocephalus and spinal cord compression. Because MRI needs to be performed under sedation and/or intubation in individuals with the early progressive form, there is an increased risk of compromising the upper airway. See <a href="#hunter.Prevention_of_Secondary_Complicat">Prevention of Secondary Complications</a>.</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation</div></li><li class="half_rhythm"><div>Developmental assessment</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hunter.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management guidelines for individuals with MPS II have been published [<a class="bk_pop" href="#hunter.REF.scarpa.2011.72">Scarpa et al 2011</a>].</p><p>At this time, treatment of complications in MPS II is symptomatic.</p><p>The involvement of specialists for each <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> organ system is required to monitor and treat specific problems (see <a href="#hunter.Clinical_Description">Clinical Description</a>). Commonly required interventions include the following:</p><ul><li class="half_rhythm"><div>Developmental, occupational, and physical therapy</div></li><li class="half_rhythm"><div>Shunting for hydrocephalus</div></li><li class="half_rhythm"><div>Tonsillectomy and adenoidectomy</div></li><li class="half_rhythm"><div>Positive pressure ventilation (CPAP or tracheostomy)</div></li><li class="half_rhythm"><div>Carpal tunnel release</div></li><li class="half_rhythm"><div>Cardiac valve replacement</div></li><li class="half_rhythm"><div>Inguinal hernia repair</div></li><li class="half_rhythm"><div>Hip replacement</div></li></ul><p>Enzyme replacement therapy (ERT) (see <a href="#hunter.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>) has shown encouraging results in possibly modifying/correcting the non-CNS manifestations, as confirmed in a long-term study [<a class="bk_pop" href="#hunter.REF.lampe.2014b.823">Lampe et al 2014b</a>].</p></div><div id="hunter.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p><b>Enzyme replacement therapy (ERT).</b> It is now a decade since ERT with intravenous idursulfase (Elaprase<sup>&#x000ae;</sup>), a recombinant form of human iduronate 2-sulfatase, has been approved in the United States and the European Union at a weekly dose of 0.5 mg/kg for the treatment of MPS II. The approval was mainly based on the results from a first trial on individuals with the slowly progressive form of the disease [<a class="bk_pop" href="#hunter.REF.muenzer.2006.465">Muenzer et al 2006</a>]. In the following year several other studies were undertaken to investigate clinical safety and efficacy of ERT; these clearly showed that idursulfase has positive effects on functional capacity (distance walked in 6 minutes and forced vital capacity), liver and spleen volumes, and urine GAGs excretion [<a class="bk_pop" href="#hunter.REF.da_silva.2016.cd008185">da Silva et al 2016</a>]. Recently, a 3.5-year independent study determined that long-term use of ERT is similarly effective in young (age 1.6 to 12 years at the start of ERT) and older individuals (age 12 to 27 years at the start of ERT) [<a class="bk_pop" href="#hunter.REF.tomanin.2014.129">Tomanin et al 2014</a>, <a class="bk_pop" href="#hunter.REF.muenzer.2017.161">Muenzer et al 2017</a>]. In addition, two recent studies have confirmed ERT efficacy in improving somatic signs and symptoms of the disease in all individuals, including infants younger than age one year and individuals with the early progressive MPS II <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#hunter.REF.lampe.2014a.99">Lampe et al 2014a</a>, <a class="bk_pop" href="#hunter.REF.lampe.2014b.823">Lampe et al 2014b</a>].</p><p>A real breakthrough in understanding the effect of ERT has been provided by the recent analysis of data from the Hunter Outcome Survey (HOS), which showed that survival in idursulfase-treated individuals was higher than in those who were untreated [<a class="bk_pop" href="#hunter.REF.burton.2017.867">Burton et al 2017</a>]. An additional report from the analysis of the HOS data, investigating clinical outcomes after up to three years of idursulfase treatment in a broad population of individuals with MPS II, suggests that the treatment improves GAG storage (as evidenced by decreases in urinary GAG levels and hepatosplenomegaly) as well as results on the six-minute walk test, left ventricular mass index, absolute forced vital capacity, and absolute forced expiratory volume in 1 second [<a class="bk_pop" href="#hunter.REF.muenzer.2017.161">Muenzer et al 2017</a>].</p><p>Since Elaprase<sup>&#x000ae;</sup> does not cross the blood-brain barrier, no effect on CNS disease is anticipated; however, there is reason to believe that somatic manifestations of those with severe CNS involvement would benefit from ERT. The young age does not add safety concerns, and individuals have significant amelioration of somatic symptoms [<a class="bk_pop" href="#hunter.REF.lampe.2014a.99">Lampe et al 2014a</a>].</p><p>Infusion-related reactions that may occur with use of Elaprase<sup>&#x000ae;</sup> ERT are comparable to similar reactions seen with other ERT products used in treatment of lysosomal storage disease and with other infused proteins such as monoclonal antibodies (e.g., infliximab). The etiology of the more severe forms of these non-allergic reactions, referred to as anaphylactoid, is unknown. Current evidence suggests that anaphylactoid (as opposed to anaphylactic) reactions are not immune mediated [<a class="bk_pop" href="#hunter.REF.mayer.2006.857">Mayer &#x00026; Young 2006</a>].</p><p>Infusion reactions are generally mild and include brief, insignificant decreases or increases in heart rate, blood pressure, or respiratory rate; itching; rash; flushing; and headache. Mild reactions can usually be managed by slowing the infusion rate for several treatments and then slowly returning to the prior rate.</p><p>Pretreatment with anti-inflammatory drugs or antihistamines, as is often done for ERT in other conditions, is not suggested on the label for Elaprase<sup>&#x000ae;</sup>; however, if mild or moderate infusion reactions (e.g., dyspnea, urticaria, or systolic blood pressure changes of &#x02264;20 mm Hg) cannot be ameliorated by slowing the infusion rate, the addition of treatment one hour before infusion with diphenhydramine and acetaminophen (or ibuprofen) to the regimen usually resolves the problem. Pretreatment can typically be discontinued after six to ten weeks.</p><p>Severe non-allergic anaphylactoid reactions such as major changes in blood pressure, wheezing, stridor, rigors, or drop in oxygen saturations should be immediately addressed by stopping the infusion and giving appropriate doses of subcutaneous epinephrine, intravenous (IV) diphenhydramine, and hydrocortisone or methylpredinsolone. Subsequent infusions should then be given at a significantly reduced rate with pretreatment with prednisone 24 hours and eight hours before the infusion, diphenhydramine and acetaminophen or ibuprofen orally one hour before the infusion, and IV methylpredinsolone just before beginning the infusion.</p><p>Current data are insufficient to indicate whether the incidence or severity of infusion-related reactions is different for individuals younger than age five years with severe respiratory compromise or with severe CNS disease. Further studies and longer follow up are needed to better understand the effects of ERT. A recent attempt to assess the impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy did not establish a clear association between infusion-related adverse events and antibody levels [<a class="bk_pop" href="#hunter.REF.giugliani.2017.2">Giugliani et al 2017</a>].</p><p>In order to overcome the limitations in the treatment of the CNS, intrathecal ERT and <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> are currently under investigation as future therapies [<a class="bk_pop" href="#hunter.REF.motas.2016.e86696">Motas et al 2016</a>, <a class="bk_pop" href="#hunter.REF.stapleton.2017.295">Stapleton et al 2017</a>]. Shire recently sponsored a Phase I/II clinical trial examining the use of intrathecal iduronate-2-sulfatase in young individuals with MPS II with CNS involvement (see <a href="https://clinicaltrials.gov/ct2/show/NCT02055118" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Trials</a>).</p><p><b>Hematopoietic stem cell transplantation (HSCT)</b> using umbilical cord blood or bone marrow is a potential way of providing sufficient enzyme activity to slow or stop the progression of the disease [<a class="bk_pop" href="#hunter.REF.guffon.2009.733">Guffon et al 2009</a>, <a class="bk_pop" href="#hunter.REF.annibali.2013.487">Annibali et al 2013</a>]; however, the use of HSCT is controversial because of the associated high risk of morbidity and mortality. Furthermore, it remains unclear if treatment early in life significantly reduces the progression of neurologic disease [<a class="bk_pop" href="#hunter.REF.mullen.2000.1093">Mullen et al 2000</a>], and anecdotal case reports published to date have been disappointing, quite unlike the reports of bone marrow transplantation (BMT) in <a href="/books/n/gene/mps1/">Hurler syndrome</a> (MPS I). Overall, the efficacy of BMT for MPS II cannot be determined until a number of children with MPS II younger than age two years with known or probable severe CNS disease undergo transplantation [<a class="bk_pop" href="#hunter.REF.tanaka.2012.513">Tanaka et al 2012</a>]. A recent single report of seven-year follow up of a prenatally diagnosed boy with MPS II who received HSCT with umbilical cord blood cells at age 70 days suggest that cognitive skills were preserved [<a class="bk_pop" href="#hunter.REF.barth.2017.62">Barth et al 2017</a>]. It has been shown that HSCT and ERT have equal efficacy in restoring growth in children with MPS II; both treatments are limited by age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and disease progression (e.g., neurologic and heart impairment) at the start of treatment [<a class="bk_pop" href="#hunter.REF.patel.2014.5">Patel et al 2014</a>]. Nevertheless, the use of HSCT has been controversial because of limited information regarding the long-term outcomes and the associated high risk of morbidity and mortality. Until two decades ago, HSCT had high mortality rates because of (1) the preconditioning regimen prior to HSCT, which caused severe side effects including increased susceptibility to infection and (2) poor donor selection, which resulted in a high risk of graft-versus-host disease [<a class="bk_pop" href="#hunter.REF.stapleton.2017.295">Stapleton et al 2017</a>]. With the development of new conditioning protocols and the creation of bone marrow donor registries and umbilical cord banks, HSCT has become more accessible [<a class="bk_pop" href="#hunter.REF.barth.2017.62">Barth et al 2017</a>]. Although further studies are required, HSCT should continue to be considered as a treatment option particularly because of its lower cost (compared to lifelong ERT treatment) and potential for improving quality of life for affected individuals and their families [<a class="bk_pop" href="#hunter.REF.barth.2017.62">Barth et al 2017</a>].</p></div><div id="hunter.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p>Given the risks associated with sedation with/without intubation, anesthesia is best administered in centers familiar with the potential complications in persons with MPS II. Risks associated with general anesthesia include the following:</p><ul><li class="half_rhythm"><div>Ankylosis of the temporomandibular joint can restrict oral access to the airway.</div></li><li class="half_rhythm"><div>Visualization of the vocal cords is compromised by the large tongue, GAG-infiltrated soft tissues, and large tonsils and adenoids.</div></li><li class="half_rhythm"><div>Care must be taken to avoid hyperextension of the neck secondary to atlantoaxial instability and cervicomedullary compression that may be present.</div></li></ul><p>Nasopharyngeal intubation is often necessary. When endotracheal intubation is difficult or when sedation is required for brief procedures, laryngeal mask airway may be indicated.</p><p>The risk of airway complications may continue following successful surgery. Extubation may be difficult because laryngeal edema, which has been reported up to 27 hours post surgery, may prevent maintenance of a proper airway [<a class="bk_pop" href="#hunter.REF.hopkins.1973.286">Hopkins et al 1973</a>]. Breathing a helium-oxygen mixture during extubation has been reported to relieve obstruction and improve outcome [<a class="bk_pop" href="#hunter.REF.mcgarvey.2008.905">McGarvey &#x00026; Pollack 2008</a>].</p></div><div id="hunter.Surveillance"><h3>Surveillance</h3><p>Guidelines for surveillance have been developed [<a class="bk_pop" href="#hunter.REF.scarpa.2011.72">Scarpa et al 2011</a>].</p><p>Modes of surveillance for complications over time depend, like treatment, on organ system and disease severity. Because all persons with MPS II face the same organ failure issues, with the time of failure being dependent on severity, when and how often to monitor for change cannot be generalized. However, the following studies/evaluations are likely indicated on at least a yearly basis beginning in early to mid-childhood:</p><ul><li class="half_rhythm"><div>Cardiology visit with echocardiogram</div></li><li class="half_rhythm"><div>Pulmonary clinic visit with pulmonary function testing</div></li><li class="half_rhythm"><div>Audiogram</div></li><li class="half_rhythm"><div>Ophthalmology examination, including examination through a dilated pupil to view the optic disc</div></li><li class="half_rhythm"><div>Developmental assessment</div></li><li class="half_rhythm"><div>Neurologic examination</div></li></ul><p>The following are appropriate at baseline and/or when symptoms/age dictates:</p><ul><li class="half_rhythm"><div>Sleep study for obstructive sleep apnea</div></li><li class="half_rhythm"><div>NCV study for evidence of carpal tunnel syndrome</div></li><li class="half_rhythm"><div>Head/neck MRI to document ventricular size and cervicomedullary narrowing</div></li><li class="half_rhythm"><div>Opening pressure on lumbar puncture</div></li><li class="half_rhythm"><div>Orthopedic evaluation to monitor hip disease</div></li></ul></div><div id="hunter.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Although clinical experience suggests that early diagnosis of at-risk males allows initiation of ERT before the onset of irreversible changes and often before significant disease progression [<a class="bk_pop" href="#hunter.REF.muenzer.2014.63">Muenzer 2014</a>], a recent study showed that while early diagnosis and use of ERT improved outcomes, mortality and morbidity remained high [<a class="bk_pop" href="#hunter.REF.franco.2017.183">Franco et al 2017</a>]. It is still unclear whether early diagnosis (either by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> or testing of at-risk male relatives) is beneficial as no data are available on whether early ERT improves the outcome of the somatic disease in MPS II. ERT is not expected to benefit children with the CNS form of the disease.</p><p>See <a href="#hunter.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hunter.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A number of interventions are being evaluated for potential use in MPS II.</p><p>Recently, a Phase I intrathecal delivery of iduronate 2-sulfatase was initiated (see <a href="http://clinicaltrials.gov/ct2/results?term=hunter+syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Trials</a>). Preliminary results showed no toxicity of the protein injected intrathecally at the dosage used (10 mg and 30 mg). The GAG concentration in the CSF was significantly reduced but clinical efficacy needed further evaluation [<a class="bk_pop" href="#hunter.REF.muenzer.2014">Muenzer et al 2014</a>].</p><p>Another ongoing multicenter study is evaluating the effect of a one-year course of monthly intrathecal administration of 10 mg of idursulfase on neurodevelopmental status in children with MPS II and cognitive impairment who have previously received and tolerated a minimum of four months of Elaprase<sup>&#x000ae;</sup> therapy.</p><p>Other therapies under preclinical investigation include more direct delivery of enzyme into the CNS, higher peripheral dosing regimens, small-molecule therapies such as chaperone and substrate reduction, and <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> [<a class="bk_pop" href="#hunter.REF.beck.2010.33">Beck 2010</a>]. Tissue uptake (including the brain and spinal cord) via the transferrin receptor of a fusion protein between iduronate 2-sulfatase (I2S) and a monoclonal antibody against the mouse transferrin receptor is being studied [<a class="bk_pop" href="#hunter.REF.zhou.2012.329">Zhou et al 2012</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="hunter.Genetic_Counseling"><h2 id="_hunter_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hunter.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="hunter.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disease nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: If a woman has more than one affected child and no other affected relatives and if the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> (germline mosaicism has been observed in MPS II) [<a class="bk_pop" href="#hunter.REF.froissart.2007.71">Froissart et al 2007</a>].</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) or the affected male may have a <i>de novo IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a carrier.</div></li><li class="half_rhythm"><div>On rare occasion, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females manifest findings of MPS II. This is thought to result from skewed inactivation of the normal paternally inherited X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> and expression of the maternally inherited mutated <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#hunter.REF.jurecka.2012.450">Jurecka et al 2012</a>, <a class="bk_pop" href="#hunter.REF.guill_nnavarro.2013.92">Guill&#x000e9;n-Navarro et al 2013</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in her son, the chance of transmitting it in each pregnancy is 50%. Males who inherit the <i>IDS</i> pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the <i>IDS</i> pathogenic variant will be carriers (on rare occasion, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females manifest findings of MPS II).</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is slightly greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> (germline mosaicism for an <i>IDS</i> pathogenic variant has been observed in MPS I) [<a class="bk_pop" href="#hunter.REF.froissart.2007.71">Froissart et al 2007</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters, who will be (heterozygotes) carriers and will usually not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>;</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes (carriers) for the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and the aunts' offspring, depending on their gender, may be at risk of being heterozygotes (carriers) for the pathogenic variant or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div><div id="hunter.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p><b>Molecular genetic testing.</b> Carrier testing for at-risk female relatives requires <b>one</b> of the following:</p><ul><li class="half_rhythm"><div>Testing for the family-specific <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male relative, OR</div></li><li class="half_rhythm"><div>If an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>:</div><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">First by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a></p></dd><dt>2.</dt><dd><p class="no_top_margin">If no <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, use of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> methods to detect intragenic and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions</p></dd><dt>3.</dt><dd><p class="no_top_margin">If no <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, use of appropriate molecular methods to detect complex rearrangements from <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> between <i>IDS</i> and the <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>, <i>IDSP1</i>, or other processes</p></dd></dl></li></ul><p><b>Biochemical genetic testing.</b> Measurement of I2S enzyme activity is not reliable for detection of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females as a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> may have normal I2S enzyme activity resulting from <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> that may be non-random.</p></div><div id="hunter.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hunter.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on testing at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hunter.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible. In families in which the causative <i>IDS</i> pathogenic variant has been identified, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> should be performed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, as assay of I2S enzyme activity is more difficult.</p><p><b>Biochemical genetic testing.</b> Prenatal testing is technically feasible for pregnancies at increased risk for MPS II by measuring I2S enzyme activity in cultured cells obtained by amniocentesis usually performed at approximately 15 to 18 weeks' gestation or chorionic villus sampling (CVS) at approximately ten to 12 weeks' gestation. However, such testing is not readily available. (Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.)</p></div></div><div id="hunter.Resources"><h2 id="_hunter_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Canadian Society for Mucopolysaccharide and Related Diseases, Inc.</b></div><div>PO Box 30034</div><div>North Vancouver British Columbia V7H 2Y8</div><div>Canada</div><div><b>Phone:</b> 800-667-1846 (toll free); 604-924-5130</div><div><b>Fax:</b> 604-924-5131</div><div><b>Email:</b> info@mpssociety.ca</div><div><a href="http://www.mpssociety.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.ca</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001203.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hunter syndrome</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Mucopolysaccharidosis%20Type%20II&#x00026;parent=Metabolic%20Disorders&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mucopolysaccharidosis Type II</a></div></li><li class="half_rhythm"><div><b>National MPS Society</b></div><div>PO Box 14686</div><div>Durham NC 27709-4686</div><div><b>Phone:</b> 877-677-1001 (toll-free); 919-806-0101</div><div><b>Fax:</b> 919-806-2055</div><div><b>Email:</b> info@mpssociety.org</div><div><a href="http://www.mpssociety.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.org</a></div></li><li class="half_rhythm"><div><b>Society for Mucopolysaccharide Diseases (MPS)</b></div><div>MPS House Repton Place</div><div>White Lion Road</div><div>Amersham Buckinghamshire HP7 9LP</div><div>United Kingdom</div><div><b>Phone:</b> 0345 389 9901</div><div><b>Email:</b> mps@mpssociety.co.uk</div><div><a href="http://www.mpssociety.co.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.co.uk</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div>RareCareSM</div><div><b>Phone:</b> 800-999-6673</div><div><a href="https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs-2/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Assistance Programs</a></div></li></ul></div><div id="hunter.Molecular_Genetics"><h2 id="_hunter_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hunter.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Mucopolysaccharidosis Type II: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1274/table/hunter.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hunter.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hunter.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hunter.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hunter.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hunter.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hunter.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hunter.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hunter.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3423" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>IDS</i></a></td><td headers="hd_b_hunter.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3423" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq28</a></td><td headers="hd_b_hunter.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P22304" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Iduronate 2-sulfatase</a></td><td headers="hd_b_hunter.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/IDS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IDS @ LOVD</a></td><td headers="hd_b_hunter.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=IDS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IDS</a></td><td headers="hd_b_hunter.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=IDS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IDS</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hunter.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hunter.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Mucopolysaccharidosis Type II (<a href="/omim/300823,309900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1274/table/hunter.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hunter.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300823" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300823</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IDURONATE 2-SULFATASE; IDS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/309900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">309900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>IDS</i> consists of nine exons and spans about 24 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. An <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>, <i>IDSP1</i>, is located about 25 kb telomeric to <i>IDS</i>. Homologous regions shared by <i>IDS</i> and <i>IDSP1</i> predispose to unequal <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> events, leading to complex rearrangements and sometimes large deletions. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1274/#hunter.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 300 <i>IDS</i> pathogenic variants have been described, the majority being single-nucleotide variants or small deletions [<a class="bk_pop" href="#hunter.REF.froissart.2007.71">Froissart et al 2007</a>]. Novel pathogenic variants are being identified continuously [<a class="bk_pop" href="#hunter.REF.brusiusfacchin.2014.133">Brusius-Facchin et al 2014</a>]. Up to 18% of MPS II results from <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one or more exons or the whole <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, and/or complex rearrangements, typically associated with the early progressive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Lack of <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>/<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation is demonstrated by identification of several pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants (<a class="figpopup" href="/books/NBK1274/table/hunter.T.ids_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="fighunterTidspathogenicvariantsdiscuss" rid-ob="figobhunterTidspathogenicvariantsdiscuss">p.Arg468Gln</a>, <a class="figpopup" href="/books/NBK1274/table/hunter.T.ids_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="fighunterTidspathogenicvariantsdiscuss" rid-ob="figobhunterTidspathogenicvariantsdiscuss">p.Arg468Trp</a>, and <a class="figpopup" href="/books/NBK1274/table/hunter.T.ids_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="fighunterTidspathogenicvariantsdiscuss" rid-ob="figobhunterTidspathogenicvariantsdiscuss">p.Ser333Leu</a>) in individuals with the early progressive phenotype and others with the intermediate or slowly progressive phenotype. At least two sibships of one brother with the early progressive phenotype and another brother with a slowly progressive phenotype have been reported [<a class="bk_pop" href="#hunter.REF.yatziv.1977.319">Yatziv et al 1977</a>].</p><ul><li class="half_rhythm"><div>Missense variants make up the majority of IDS pathogenic variants, resulting in reduced expression of I2S enzyme activity and variable disease severity. Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> predictions are not reliable in these cases.</div></li><li class="half_rhythm"><div>In males with large deletions and intragenic rearrangements, no enzyme is produced and these individuals typically have the early progressive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (see <a href="#hunter.GenotypePhenotype_Correlations">Genotype Phenotype Correlations</a>).</div></li></ul><p>A 178-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in the <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a> was identified in two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with low enzyme activity [<a class="bk_pop" href="#hunter.REF.brusiusfacchin.2013.150">Brusius-Facchin et al 2013</a>]. Alteration of the promoter region may explain low enzyme activity in some affected individuals in whom no <i>IDS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> or (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletion was detected.</p><div id="hunter.T.ids_pathogenic_variants_discuss" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>IDS</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1274/table/hunter.T.ids_pathogenic_variants_discuss/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hunter.T.ids_pathogenic_variants_discuss_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.998C&#x0003e;T</td><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser333Leu</td><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000202.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000202<wbr style="display:inline-block"></wbr>​.5</a><br /><a href="/protein/NP_000193.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000193<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1403G&#x0003e;A</td><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg468Gln</td></tr><tr><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1402C&#x0003e;T</td><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg468Tryp</td></tr><tr><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1122C&#x0003e;T</td><td headers="hd_h_hunter.T.ids_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splice variant</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Iduronate 2-sulfatase (I2S), a 550-amino-acid protein, catalyzes the release of sulfate from the iduronate sulfate residues of heparan sulfate and dermatan sulfate [<a class="bk_pop" href="#hunter.REF.neufeld.2015">Neufeld &#x00026; Muenzer 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>IDS</i> result in absence or reduced levels of I2S enzyme activity, which decreases the amount of the sulfate moiety released from the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate during their degradation, disrupting cellular function and causing disease.</p></div><div id="hunter.References"><h2 id="_hunter_References_">References</h2><div id="hunter.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.annibali.2013.487">Annibali R, Caponi L, Morganti A, Manna M, Gabrielli O, Ficcadenti A. Hunter syndrome (mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation. <span><span class="ref-journal">Minerva Pediatr. </span>2013;<span class="ref-vol">65</span>:487–96.</span> [<a href="/pubmed/24056375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24056375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.ashworth.2006.1">Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. <span><span class="ref-journal">Surv Ophthalmol. </span>2006;<span class="ref-vol">51</span>:1–17.</span> [<a href="/pubmed/16414358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16414358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.baehner.2005.1011">Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschutter A, Kampmann C, Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. <span><span class="ref-journal">J Inherit Metab Dis. </span>2005;<span class="ref-vol">28</span>:1011–7.</span> [<a href="/pubmed/16435194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16435194</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.barth.2017.62">Barth AL, de Magalh&#x000e3;es TSPC, Reis ABR, de Oliveira ML, Scalco FB, Cavalcanti NC, Silva DSE, Torres DA, Costa AAP, Bonfim C, Giugliani R, Llerena JC Jr, Horovitz DDG. Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-up. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2017;<span class="ref-vol">12</span>:62–8.</span> [<a href="/pmc/articles/PMC5470531/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5470531</span></a>] [<a href="/pubmed/28649514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28649514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.beck.2010.33">Beck M. Therapy for lysosomal storage disorders. <span><span class="ref-journal">IUBMB Life. </span>2010;<span class="ref-vol">62</span>:33–40.</span> [<a href="/pubmed/20014233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20014233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.brusiusfacchin.2013.150">Brusius-Facchin AC, Abrah&#x000e3;o L, Schwartz IV, Louren&#x000e7;o CM, Santos ES, Zanetti A, Tomanin R, Scarpa M, Giugliani R, Leistner-Segal S. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence. <span><span class="ref-journal">Gene. </span>2013;<span class="ref-vol">526</span>:150–4.</span> [<a href="/pubmed/23707223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23707223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.brusiusfacchin.2014.133">Brusius-Facchin AC, Schwartz IV, Zimmer C, Ribeiro MG, Acosta AX, Horovitz D, Monlle&#x000f3; IL, Fontes MI, Fett-Conte A, Sobrinho RP, Duarte AR, Boy R, Mabe P, Ascurra M, de Michelena M, Tylee KL, Besley GT, Garreton MC, Giugliani R, Leistner-Segal S. Mucopolysaccharidosis type II: identification of 30 novel mutations among Latin American patients. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:133–8.</span> [<a href="/pubmed/24125893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24125893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.burton.2017.867">Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). <span><span class="ref-journal">J Inherit Metab Dis. </span>2017;<span class="ref-vol">40</span>:867–74.</span> [<a href="/pubmed/28887757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28887757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.caruso.1986.1612">Caruso RC, Kaiser-Kupfer MI, Muenzer J, Ludwig IH, Zasloff MA, Mercer PA. Electroretinographic findings in the mucopolysaccharidoses. <span><span class="ref-journal">Ophthalmology. </span>1986;<span class="ref-vol">93</span>:1612–6.</span> [<a href="/pubmed/3101020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3101020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.collins.1990.1445">Collins ML, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. <span><span class="ref-journal">Ophthalmology. </span>1990;<span class="ref-vol">97</span>:1445–9.</span> [<a href="/pubmed/2123975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2123975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.da_silva.2016.cd008185">da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2016;<span class="ref-vol">2</span>:CD008185.</span> [<a href="/pubmed/26845288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26845288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.franco.2017.183">Franco JFDS, El Dib R, Agarwal A, Soares D, Milhan NVM, Albano LMJ, Kim CA. Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: results from a single-center case series study. <span><span class="ref-journal">Intractable Rare Dis Res. </span>2017;<span class="ref-vol">6</span>:183–90.</span> [<a href="/pmc/articles/PMC5608928/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5608928</span></a>] [<a href="/pubmed/28944140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28944140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.froissart.2007.71">Froissart R, Da Silva IM, Maire I. Mucopolysaccharidosis type II: an update on mutation spectrum. <span><span class="ref-journal">Acta Paediatr. </span>2007;<span class="ref-vol">96</span>:71–7.</span> [<a href="/pubmed/17391447" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17391447</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.giugliani.2017.2">Giugliani R, Harmatz P, Jones SA, Mendelsohn NJ, Vellodi A, Qiu Y, Hendriksz CJ, Vijayaraghavan S, Whiteman DA, Pano A. Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2017;<span class="ref-vol">12</span>:2–7.</span> [<a href="/pmc/articles/PMC5320046/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5320046</span></a>] [<a href="/pubmed/28243577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28243577</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.guffon.2009.733">Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. <span><span class="ref-journal">J Pediatr. </span>2009;<span class="ref-vol">154</span>:733–7.</span> [<a href="/pubmed/19167723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19167723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.guill_nnavarro.2013.92">Guill&#x000e9;n-Navarro E, Domingo-Jim&#x000e9;nez MR, Alcalde-Mart&#x000ed;n C, Cancho-Candela R, Couce ML, Gal&#x000e1;n-G&#x000f3;mez E, Alonso-Luengo O. Clinical manifestations in female carriers of mucopolysaccharidosis type II: a spanish cross-sectional study. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:92.</span> [<a href="/pmc/articles/PMC3697996/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3697996</span></a>] [<a href="/pubmed/23800320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23800320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.holt.2011.320">Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. <span><span class="ref-journal">J Pediatr. </span>2011;<span class="ref-vol">159</span>:320–6.e2.</span> [<a href="/pubmed/21530981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21530981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.hopkins.1973.286">Hopkins R, Watson JA, Jones JH, Walker M. Two cases of Hunter's syndrome--the anaesthetic and operative difficulties in oral surgery. <span><span class="ref-journal">Br J Oral Surg. </span>1973;<span class="ref-vol">10</span>:286–99.</span> [<a href="/pubmed/4198586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4198586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.johnson.2013.17">Johnson BA, van Diggelen OP, Dajnoki A, Bodamer OA. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type II. <span><span class="ref-journal">Curr Protoc Hum Genet. </span>2013;<span class="ref-vol">79</span>:17.</span> [<a href="/pubmed/24510650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24510650</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.jurecka.2012.450">Jurecka A, Krumina Z, &#x0017b;uber Z, R&#x000f3;&#x0017c;d&#x0017c;y&#x00144;ska-&#x0015a;wi&#x00105;tkowska A, K&#x00142;oska A, Czartoryska B, Tylki-Szyma&#x00144;ska A. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:450–4.</span> [<a href="/pubmed/22246721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22246721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.kamin.2008.57">Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. <span><span class="ref-journal">Acta Paediatr. </span>2008;<span class="ref-vol">97</span>:57–60.</span> [<a href="/pubmed/18339190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18339190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.lampe.2014a.99">Lampe C, Atherton A, Burton BK, Descartes M, Giugliani R, Horovitz DD, Kyosen SO, Magalh&#x000e3;es TS, Martins AM, Mendelsohn NJ, Muenzer J, Smith LD. Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age. <span><span class="ref-journal">JIMD Rep. </span>2014a;<span class="ref-vol">14</span>:99–113.</span> [<a href="/pmc/articles/PMC4213327/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4213327</span></a>] [<a href="/pubmed/24515576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24515576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.lampe.2014b.823">Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, Muschol N, Olson R, Mendelsohn NJ. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a phenotype: an international case series. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014b;<span class="ref-vol">37</span>:823–9.</span> [<a href="/pmc/articles/PMC4158409/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4158409</span></a>] [<a href="/pubmed/24596019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24596019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.leung.1971.32">Leung LS, Weinstein GW, Hobson R. Further electroretinographic studies of patients with mucopolysaccharidoses. <span><span class="ref-journal">Birth Defects Orig Artic Ser. </span>1971:32–40.</span> [<a href="/pubmed/5006141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5006141</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.lualdi.2005.491">Lualdi S, Regis S, Di Rocco M, Corsolini F, Stroppiano M, Antuzzi D, Filocamo M. Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with mucopolysaccharidosis type II revealed by a rapid PCR-based method. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:491–7.</span> [<a href="/pubmed/15832315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15832315</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.mayer.2006.857">Mayer L, Young Y. Infusion reactions and their management. <span><span class="ref-journal">Gastroenterol Clin North Am. </span>2006;<span class="ref-vol">35</span>:857–66.</span> [<a href="/pubmed/17129817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17129817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.mcgarvey.2008.905">McGarvey JM, Pollack CV. Heliox in airway management. <span><span class="ref-journal">Emerg Med Clin North Am. </span>2008;<span class="ref-vol">26</span>:905–20.</span> [<a href="/pubmed/19059090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19059090</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.motas.2016.e86696">Motas S, Haurigot V, Garcia M, Marc&#x000f3; S, Ribera A, Roca C, S&#x000e1;nchez X, S&#x000e1;nchez V, Molas M, Bertolin J, Maggioni L, Le&#x000f3;n X, Ruberte J, Bosch F. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). <span><span class="ref-journal">JCI Insight. </span>2016;<span class="ref-vol">1</span>:e86696.</span> [<a href="/pmc/articles/PMC5033872/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5033872</span></a>] [<a href="/pubmed/27699273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27699273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.muenzer.2014.63">Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:63–72.</span> [<a href="/pubmed/24388732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24388732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.muenzer.2009.e1228">Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, Link B, Martin RA, Molter DW, Mu&#x000f1;oz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E. Multidisciplinary management of Hunter syndrome. <span><span class="ref-journal">Pediatrics. </span>2009;<span class="ref-vol">124</span>:e1228–39.</span> [<a href="/pubmed/19901005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19901005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.muenzer.2014">Muenzer J, Christian J, Hendriks Z, Stein MB, Fan Z, Kearney S, Horton J, Vijayaraghavan S, Perry V, Santra S, Guirish A, Luying Pan S, Wang N, Mascelli M, Sciarappa K, Barbier AJ. Investigational intrathecal enzyme replacement therapy for children with severe form of Hunter syndrome (mucopolysaccharidosis II). Abstract 1126. Sauipe, Bahia, Brazil: 13th International Symposium on Mucopolysaccharidoses and Related Diseases. 2014.</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.muenzer.2017.161">Muenzer J, Giugliani R, Scarpa M, Tylki-Szyma&#x00144;ska A, Jego V, Beck M. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the Hunter Outcome Survey (HOS). <span><span class="ref-journal">Orphanet J Rare Dis. </span>2017;<span class="ref-vol">12</span>:161.</span> [<a href="/pmc/articles/PMC5627440/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5627440</span></a>] [<a href="/pubmed/28974237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28974237</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.muenzer.2006.465">Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). <span><span class="ref-journal">Genet Med. </span>2006;<span class="ref-vol">8</span>:465–73.</span> [<a href="/pubmed/16912578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16912578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.mullen.2000.1093">Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. <span><span class="ref-journal">Bone Marrow Transplant. </span>2000;<span class="ref-vol">25</span>:1093–7.</span> [<a href="/pubmed/10828871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10828871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.nelson.2003.310">Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">123A</span>:310–3.</span> [<a href="/pubmed/14608657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14608657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.neufeld.2015">Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <em>The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</em>. Chap 136. New York, NY: McGraw-Hill. 2015.</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.oshima.2011.516">Oshima J, Lee JA, Breman AM, Fernandes PH, Babovic-Vuksanovic D, Ward PA, Wolfe LA, Eng CM, Del Gaudio D. LCR-initiated rearrangements at the IDS locus, completed with Alu-mediated recombination or non-homologous end joining. <span><span class="ref-journal">J Hum Genet. </span>2011;<span class="ref-vol">56</span>:516–23.</span> [<a href="/pubmed/21593745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21593745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.patel.2014.5">Patel P, Suzuki Y, Maeda M, Yasuda E, Shimada T, Orii KE, Orii T, Tomatsu S. Growth charts for patients with Hunter syndrome. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2014;<span class="ref-vol">1</span>:5–18.</span> [<a href="/pmc/articles/PMC4060980/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4060980</span></a>] [<a href="/pubmed/24955330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24955330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.probst.2007.1358">Probst FJ, Roeder ER, Enciso VB, Ou Z, Cooper ML, Eng P, Li J, Gu Y, Stratton RF, Chinault AC, Shaw CA, Sutton VR, Cheung SW, Nelson DL. Chromosomal microarray analysis (CMA) detects a large X chromosome deletion including FMR1, FMR2, and IDS in a female patient with mental retardation. <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:1358–65.</span> [<a href="/pubmed/17506108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17506108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.rapoport.2017.49">Rapoport DM, Mitchell JJ. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses. <span><span class="ref-journal">Mol Genet Metab. </span>2017;<span class="ref-vol">122S</span>:49–54.</span> [<a href="/pubmed/28964643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28964643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.scarpa.2011.72">Scarpa M, Alm&#x000e1;ssy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guill&#x000e9;n-Navarro E, Hensman P, Jones S, Kamin W, Kampmann C, Lampe C, Lavery CA, Teles EL, Link B, Lund AM, Malm G, Pitz S, Rothera M, Stewart C, Tylki-Szyma&#x00144;ska A, van der Ploeg A, Walker R, Zeman J, Wraith JE., Hunter Syndrome European Expert Council.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2011;<span class="ref-vol">6</span>:72.</span> [<a href="/pmc/articles/PMC3223498/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3223498</span></a>] [<a href="/pubmed/22059643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22059643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.schulzefrenking.2011.203">Schulze-Frenking G, Jones SA, Roberts J, Beck M, Wraith JE. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:203–8.</span> [<a href="/pmc/articles/PMC3026660/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3026660</span></a>] [<a href="/pubmed/20978944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20978944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.stapleton.2017.295">Stapleton M, Kubaski F, Mason RW, Yabe H, Suzuki Y, Orii KE, Orii T, Tomatsu S. Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome). <span><span class="ref-journal">Expert Opin Orphan Drugs. </span>2017;<span class="ref-vol">5</span>:295–307.</span> [<a href="/pmc/articles/PMC5693349/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5693349</span></a>] [<a href="/pubmed/29158997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29158997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.suppiej.2013.1203">Suppiej A, Rampazzo A, Cappellari A, Traverso A, Tormene AP, Pinello L, Scarpa M. The role of visual electrophysiology in mucopolysaccharidoses. <span><span class="ref-journal">J Child Neurol. </span>2013;<span class="ref-vol">28</span>:1203–9.</span> [<a href="/pubmed/22914380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22914380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.tanaka.2012.513">Tanaka A, Okuyama T, Suzuki Y, Sakai N, Takakura H, Sawada T, Tanaka T, Otomo T, Ohashi T, Ishige-Wada M, Yabe H, Ohura T, Suzuki N, Kato K, Adachi S, Kobayashi R, Mugishima H, Kato S. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">107</span>:513–20.</span> [<a href="/pubmed/23022072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23022072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.tomanin.2014.129">Tomanin R, Zanetti A, D'Avanzo F, Rampazzo A, Gasparotto N, Parini R, Pascarella A, Concolino D, Procopio E, Fiumara A, Borgo A, Frigo A, Scarpa M. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014;<span class="ref-vol">9</span>:129.</span> [<a href="/pmc/articles/PMC4180060/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4180060</span></a>] [<a href="/pubmed/25231261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25231261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.tylkiszyma_ska.2014.107">Tylki-Szyma&#x00144;ska A. Mucopolysaccharidosis type II, Hunter's syndrome. <span><span class="ref-journal">Pediatr Endocrinol Rev. </span>2014;<span class="ref-vol">12</span> Suppl 1:107–13.</span> [<a href="/pubmed/25345092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25345092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.vollebregt.2017.1063">Vollebregt AAM, Hoogeveen-Westerveld M, Kroos MA, Oussoren E, Plug I, Ruijter GJ, van der Ploeg AT, Pijnappel WWMP. Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype. <span><span class="ref-journal">Dev Med Child Neurol. </span>2017;<span class="ref-vol">59</span>:1063–70.</span> [<a href="/pubmed/28543354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28543354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.wraith.2008.508">Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J, Investigators HOS. Initial report from the Hunter Outcome Survey. <span><span class="ref-journal">Genet Med. </span>2008;<span class="ref-vol">10</span>:508–16.</span> [<a href="/pubmed/18580692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18580692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.yatziv.1977.319">Yatziv S, Erickson RP, Epstein CJ. Mild and Hunter syndrome (MPS II) within the same sibships. <span><span class="ref-journal">Clin Genet. </span>1977;<span class="ref-vol">11</span>:319–26.</span> [<a href="/pubmed/140775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 140775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.young.1981.201">Young ID, Harper PS. Psychosocial problems in Hunter's syndrome. <span><span class="ref-journal">Child Care Health Dev. </span>1981;<span class="ref-vol">7</span>:201–9.</span> [<a href="/pubmed/6793262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6793262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hunter.REF.zhou.2012.329">Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. <span><span class="ref-journal">Drug Metab Dispos. </span>2012;<span class="ref-vol">40</span>:329–35.</span> [<a href="/pubmed/22065691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22065691</span></a>]</div></li></ul></div></div><div id="hunter.Chapter_Notes"><h2 id="_hunter_Chapter_Notes_">Chapter Notes</h2><div id="hunter.Author_Notes"><h3>Author Notes</h3><p>Dr Maurizio Scarpa is the Director of the <a href="https://www.helios-gesundheit.de/kliniken/wiesbaden-hsk/unser-angebot/zentrum-fuer-seltene-erkrankungen/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Center for Rare Diseases</a> at the Horst Schmidt Klinik in Wiesbaden, Germany. He is also the President of the <a href="http://www.brains4brain.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Brains for Brain Foundation (B4B)</a>. B4B aims to develop new and innovative therapeutic strategies to cross the blood-brain barrier and supports the following activities in the field of rare neurologic disorders: scientific research, knowledge dissemination, social and socio-medical assistance, and health assistance.</p></div><div id="hunter.Author_History"><h3>Author History</h3><p>Rick A Martin, MD; Saint Louis University (2007-2011)<br />Maurizio Scarpa, MD, PhD (2011-present)</p></div><div id="hunter.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>4 October 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 March 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 February 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 November 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>8 June 2007 (rm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1274</span><span class="label">PMID: <a href="/pubmed/20301451" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301451</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mps1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mps3/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1274&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1274/?report=reader">PubReader</a></li><li><a href="/books/NBK1274/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1274" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1274" style="display:none" title="Cite this Page"><div class="bk_tt">Scarpa M. Mucopolysaccharidosis Type II. 2007 Nov 6 [Updated 2018 Oct 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1274/pdf/Bookshelf_NBK1274.pdf">PDF version of this page</a> (230K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hunter.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hunter.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hunter.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hunter.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hunter.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hunter.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hunter.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hunter.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hunter.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hunter.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hunter.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3423[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">IDS</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1485994" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1485994" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1485994" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1485994" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301341" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Clarke LA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23844448" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type IVA</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type IVA<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Regier DS, Oetgen M, Tanpaiboon P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301567" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Otopalatodigital Spectrum Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Otopalatodigital Spectrum Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Robertson S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301398" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Simpson-Golabi-Behmel Syndrome Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Simpson-Golabi-Behmel Syndrome Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sajorda BJ, Gonzalez-Gandolfi CX, Hathaway ER, Kalish JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301451" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301451" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040beb75f66d18aa7e8de4">Mucopolysaccharidosis Type II - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Mucopolysaccharidosis Type II - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:24:59-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88D496E03FBB110000000006390204&amp;ncbi_session=CE88D496E040BEB1_1593SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1274%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1274&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1274/&amp;ncbi_pagename=Mucopolysaccharidosis Type II - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88D496E040BEB1_1593SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>